Clinical trial
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537
Study timeline
Study start (actual)2026-01-08Date precision: day
Registry last updated2026-09-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancer (NSCLC)unresolved
Colorectal Cancer (CRC)unresolved
Pancreatic Adenocarcinomaunresolved
Pancreatic Ductal Adenocarcinoma (PDAC)unresolved
PDACunresolved
CRCunresolved
NSCLCunresolved
Pancreatic Cancerunresolved
Lung Cancer (NSCLC)unresolved
Advanced Solid Tumorsunresolved
Interventions
RMC-5127DRUG
daraxonrasibDRUG · verified · RxNorm: daraxonrasib
cetuximabDRUG · verified · RxNorm: cetuximab
Sponsors & collaborators
Revolution Medicines, Inc.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07349537 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.